JP2005516988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516988A5 JP2005516988A5 JP2003565420A JP2003565420A JP2005516988A5 JP 2005516988 A5 JP2005516988 A5 JP 2005516988A5 JP 2003565420 A JP2003565420 A JP 2003565420A JP 2003565420 A JP2003565420 A JP 2003565420A JP 2005516988 A5 JP2005516988 A5 JP 2005516988A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical combination
- cells
- pharmaceutical
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 59
- 210000004027 cell Anatomy 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 9
- 101710095468 Cyclase Proteins 0.000 claims 8
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 8
- 125000004122 cyclic group Chemical group 0.000 claims 8
- 230000037041 intracellular level Effects 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical group COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 6
- 229950005741 rolipram Drugs 0.000 claims 6
- 210000004116 schwann cell Anatomy 0.000 claims 6
- CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 claims 4
- -1 2-pyridinylmethoxy Chemical group 0.000 claims 4
- MNHXYNNKDDXKNP-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,7-diethyl-2-pyrido[2,3-d]pyrimidinone Chemical compound N=1C(=O)N(CC)C2=NC(CC)=CC=C2C=1C1=CC=CC(Cl)=C1 MNHXYNNKDDXKNP-UHFFFAOYSA-N 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 210000005155 neural progenitor cell Anatomy 0.000 claims 4
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 claims 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 4
- DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 claims 3
- 101710157975 Cyclic nucleotide phosphodiesterase inhibitor Proteins 0.000 claims 3
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 210000004498 neuroglial cell Anatomy 0.000 claims 3
- SMPNJFHAPJOHPP-LHKKBNDGSA-N (Sp)-cAMPS Chemical compound C([C@H]1O2)O[P@@](S)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 SMPNJFHAPJOHPP-LHKKBNDGSA-N 0.000 claims 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims 2
- PDMUULPVBYQBBK-UHFFFAOYSA-N 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2NC(=O)NC2)=C1 PDMUULPVBYQBBK-UHFFFAOYSA-N 0.000 claims 2
- SQENDTSUPLIUHW-UHFFFAOYSA-N 5-(2-propoxyphenyl)-2h-triazolo[4,5-d]pyrimidine Chemical compound CCCOC1=CC=CC=C1C1=NC2=NNN=C2C=N1 SQENDTSUPLIUHW-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 claims 2
- 208000001738 Nervous System Trauma Diseases 0.000 claims 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 229960002105 amrinone Drugs 0.000 claims 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 2
- 229950002934 cilostamide Drugs 0.000 claims 2
- 229960004588 cilostazol Drugs 0.000 claims 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 229960002768 dipyridamole Drugs 0.000 claims 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 229960003574 milrinone Drugs 0.000 claims 2
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims 2
- 208000028412 nervous system injury Diseases 0.000 claims 2
- 210000001178 neural stem cell Anatomy 0.000 claims 2
- 229960000965 nimesulide Drugs 0.000 claims 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 2
- 210000000196 olfactory nerve Anatomy 0.000 claims 2
- 229950005421 olprinone Drugs 0.000 claims 2
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 claims 2
- 229960001476 pentoxifylline Drugs 0.000 claims 2
- 229960003310 sildenafil Drugs 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229960000278 theophylline Drugs 0.000 claims 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- AAZMHPMNAVEBRE-SDBHATRESA-N 8-(4-chlorophenylthio)-cAMP Chemical compound N=1C=2C(N)=NC=NC=2N([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=1SC1=CC=C(Cl)C=C1 AAZMHPMNAVEBRE-SDBHATRESA-N 0.000 claims 1
- ZDJHIEHUVPCEDK-IDTAVKCVSA-N 8-(4-chlorophenylthio)-cGMP Chemical compound N1([C@H]2[C@@H]([C@@H]3OP(O)(=O)OC[C@H]3O2)O)C=2NC(N)=NC(=O)C=2N=C1SC1=CC=C(Cl)C=C1 ZDJHIEHUVPCEDK-IDTAVKCVSA-N 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 229960005263 bucladesine Drugs 0.000 claims 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- ORZROTLRYOYVPB-UHFFFAOYSA-N methyl 2-(4-aminophenyl)-1-oxo-7-(pyridin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)isoquinoline-3-carboxylate Chemical compound C12=CC=C(OCC=3N=CC=CC=3)C=C2C(=O)N(C=2C=CC(N)=CC=2)C(C(=O)OC)=C1C1=CC(OC)=C(OC)C(OC)=C1 ORZROTLRYOYVPB-UHFFFAOYSA-N 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000037152 sensory function Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35430602P | 2002-02-07 | 2002-02-07 | |
| PCT/US2003/003513 WO2003065994A2 (en) | 2002-02-07 | 2003-02-07 | Schwann cell and phosphodiesterase inhibitors based therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516988A JP2005516988A (ja) | 2005-06-09 |
| JP2005516988A5 true JP2005516988A5 (cg-RX-API-DMAC10.html) | 2006-06-29 |
Family
ID=27734351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565420A Pending JP2005516988A (ja) | 2002-02-07 | 2003-02-07 | シュヴァン細胞およびホスホジエステラーゼインヒビターに基づく治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030220280A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1482916A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2005516988A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20040101220A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003210869A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2476275A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003065994A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| JP3886346B2 (ja) * | 2001-06-22 | 2007-02-28 | サンバイオ，インコーポレイティド | 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US8309057B2 (en) * | 2005-06-10 | 2012-11-13 | The Invention Science Fund I, Llc | Methods for elevating neurotrophic agents |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| BRPI0711816A2 (pt) * | 2006-05-19 | 2011-12-13 | Helicon Therapeutics Inc | inibidores fosfodiesterase 4 para rehabilitação motora e cognitiva |
| US7811549B2 (en) * | 2006-07-05 | 2010-10-12 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
| KR20080007800A (ko) * | 2006-07-18 | 2008-01-23 | 한훈 | 씨디34 음성 및 씨디45 양성의 제대혈 유래 줄기세포를이용한 척수 손상 세포 치료제 조성물 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| EP2200985B1 (en) | 2007-09-14 | 2011-07-13 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| CA2696948C (en) | 2007-09-14 | 2013-04-30 | Jose Maria Cid-Nunez | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| US20090185973A1 (en) * | 2008-01-22 | 2009-07-23 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
| WO2009111649A2 (en) | 2008-03-05 | 2009-09-11 | Regenerative Research Foundation | Methods and compositions for delivery of exogenous factors to nervous system sites |
| CN102143955B (zh) | 2008-09-02 | 2013-08-14 | Omj制药公司 | 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物 |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| ES2440001T3 (es) | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2588594B1 (en) | 2010-07-01 | 2022-11-30 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
| ES2552879T3 (es) | 2010-11-08 | 2015-12-02 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| WO2019099902A1 (en) * | 2017-11-17 | 2019-05-23 | The Research Foundation for State University of New York | A method for treating damaged peripheral nerves using x-ray microbeam irradiation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US134821A (en) * | 1873-01-14 | Improvement in row-locks | ||
| US6104754A (en) * | 1995-03-15 | 2000-08-15 | Kabushiki Kaisha Toshiba | Moving picture coding and/or decoding systems, and variable-length coding and/or decoding system |
| US5714385A (en) * | 1995-05-10 | 1998-02-03 | Genentech, Inc. | Media for culturing schwann cells |
| US6002802A (en) * | 1995-10-27 | 1999-12-14 | Kabushiki Kaisha Toshiba | Video encoding and decoding apparatus |
| JP3681835B2 (ja) * | 1995-12-27 | 2005-08-10 | 三菱電機株式会社 | 画像符号化装置及び画像復号化装置及び符号化・復号化システム |
| US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| US6266370B1 (en) * | 1996-09-03 | 2001-07-24 | Nippon Telegraph And Telephone Corporation | Brightness-variation compensation method and coding/decoding apparatus for moving pictures |
| US5885834A (en) * | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
| JP2002503901A (ja) * | 1998-02-13 | 2002-02-05 | クビス・インク | 飛越し走査移動画像の最適圧縮方法及び装置 |
| US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
| US6459773B1 (en) * | 2000-05-05 | 2002-10-01 | Lucent Technologies Inc. | System to pre-qualify copper subscriber loops for high bandwidth access service using subscriber or network generated tones |
| CA2427430A1 (en) * | 2000-11-02 | 2002-06-13 | Research Foundation Of City University Of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
-
2003
- 2003-02-07 EP EP03737656A patent/EP1482916A4/en not_active Withdrawn
- 2003-02-07 AU AU2003210869A patent/AU2003210869A1/en not_active Abandoned
- 2003-02-07 JP JP2003565420A patent/JP2005516988A/ja active Pending
- 2003-02-07 US US10/359,554 patent/US20030220280A1/en not_active Abandoned
- 2003-02-07 KR KR10-2004-7012106A patent/KR20040101220A/ko not_active Ceased
- 2003-02-07 WO PCT/US2003/003513 patent/WO2003065994A2/en not_active Ceased
- 2003-02-07 CA CA002476275A patent/CA2476275A1/en not_active Abandoned
-
2009
- 2009-01-30 US US12/363,388 patent/US20090136463A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516988A5 (cg-RX-API-DMAC10.html) | ||
| AU715380B2 (en) | Pyrazolopyrimidines for treatment of neuronal and other disorders | |
| RU2409576C2 (ru) | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения | |
| RU2379292C2 (ru) | Производные пиразола в качестве ингибиторов фосфодиэстеразы 4 | |
| US12240833B2 (en) | Pyridazinone compounds and uses thereof | |
| CA2483241A1 (en) | Novel diazabicyclononene derivatives | |
| RU2009133794A (ru) | Гербициды на основе замещенного n-оксида пиридина | |
| US20090053168A1 (en) | Treatments of b-cell proliferative disorders | |
| RU2003124651A (ru) | Производные триазоло[4,5-d]пиримидина и их применение в качестве антагонистов пуринергического рецептора | |
| RU2004106783A (ru) | Производные 4-амино-6-фенилпирроло[2, 3] пиримидина | |
| JP2007503443A5 (cg-RX-API-DMAC10.html) | ||
| US5175165A (en) | Antiviral combinations and compounds therefor | |
| PE20110235A1 (es) | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina | |
| CA2694987A1 (en) | Combinations for the treatment of b-cell proliferative disorders | |
| MX2011000026A (es) | Inhibidores de proteina cinasas. | |
| RU2003124653A (ru) | Производные пурина в качестве антагонистов пуринергических рецепторов | |
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| US20130040972A1 (en) | USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | |
| JP2018513190A5 (cg-RX-API-DMAC10.html) | ||
| JP2005516924A5 (cg-RX-API-DMAC10.html) | ||
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| JPS6051112A (ja) | 抗ウイルス配合組成物 | |
| JP2004525183A5 (cg-RX-API-DMAC10.html) | ||
| JP2003506438A5 (cg-RX-API-DMAC10.html) | ||
| KR950702551A (ko) | 염증 및 면역 질환의 치료용 2,5-디아릴 테트라히드로티오펜, 2,5-디아릴 테트라히드로푸란 및 그 유사물(2,5-diaryl tetrahydro-thiophene, furans and analogs for the treatment of inflamimatory and immune disorders) |